BARD1’s Shares Mounted On ASX After Developing World-First Blood Test For Breast Cancer Detection

  • Oct 24, 2018 AEDT
  • Team Kalkine
BARD1’s Shares Mounted On ASX After Developing World-First Blood Test For Breast Cancer Detection

Breast cancer is one of the most common cancer in women and it is the second leading cause of cancer overall after lung cancer. In 2018, around 2.1 million new cases were diagnosed with breast cancer and 626,679 deaths occurred due to breast cancer. The incidence rates of breast cancer are highest in Australia, Western Europe, Northern Europe, and North America.

On 23 October 2018, BARD1 Life Sciences Limited (ASX: BD1)  which is a Perth based Biotech Company, made an announcement regarding a world-first BARD1 Breast Cancer (BC) test for early detection of breast cancer. Following this news, in the last two days, the share price of the company increased by $0.038 (271.428 %) from $0.014 on 22 October to $0.052 on 24 October 2018 (AEST 2:04 PM).

This breakthrough research proves that the BARD1 BC test has high diagnostic accuracy for the detection of breast cancer across all sub-types and stages with AUC 0.86, 70% sensitivity and 88% specificity. Further BARD1 BC is capable of accurately distinguishing the malignant breast cancer from benign lesions. 

Earlier, the company has announced its success with the BARD1 Ovarian Cancer test and now the Company is planning to develop both tests in parallel using the same Luminex instrumentation platform. The combination of BARD1 Breast and BARD1 Ovarian Cancer tests will provide a tool for monitoring and early detection of cancer in high-risk women with a familial accumulation of breast/ovarian cancers or identified mutations in the BRCA1/2 genes.

The BARD1 Breast Cancer test will address an unmet need for effective screening of breast cancer and assessment of benign lesions from breast cancer to detect cancer early, save women’s lives and avoid unnecessary surgery. Breast cancer death rates have steadily decreased in recent times due to earlier detection through government screening programs using mammograms which detects cancer earlier when it is small and not spread. The increased awareness about breast cancer and better treatments have resulted in an overall 5-year survival rate in women of 90.2% in the USA, 89.5% in Australia and 87% in the UK. BARD1 is planning to conduct additional breast cancer studies to further develop, optimize and evaluate BARD1 BC for early detection of breast cancer in larger cohorts comprising different breast cancer types and stages and the company is also progressing its studies to further improve the diagnostic accuracy of BARD1 BC for early detection of breast cancer.

On 24 October 2018, BARD1 Life Sciences Limited announced that on 28 September 2018, the China National Intellectual Property Administration (CNIPA) granted Chinese Patent number 201610347489.9 entitled ‘BARD1 isoforms in lung and colorectal cancer which protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer. Following this news, the share price of the company increased by 18.182 percent as on 24 October 2018.

In the last three months, the share price of the company increased by 175 percent as on 23 October 2018. BD1’s shares traded at $0.052 with a market capitalization of $36.46 million as on 24 October 2018 (AEST 2:04 PM).

What happened to the stock price Treasury Wine Estates?

The stock price of Treasury Wine Estates (ASX: TWE) has witnessed a negative today morning as the stock price have been witnessing downward momentum. A possible reason for the fall in the company’s share price could be the fall in the US exports. At the time of writing, TWE’s stock price is trading at A$15.665 per share which implies that the stock has fallen A$0.535 per share or 3.302%. It has been trading in the lower level of the range and has a market capitalization of $11.64 billion.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK